ArticleCancer management and research2025
Erianin Suppresses Pancreatic Cancer Progression by Inducing Cell Cycle Arrest and Ferroptosis.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Erianin, a natural product, has shown anti-cancer properties in various malignancies, but its effects on pancreatic cancer and the underlying mechanisms remain poorly understood. Aim: This study aimed to evaluate the anti-tumor effects of erianin on pancreatic cancer cells and to explore the regulatory mechanisms involved. Methods: PANC-1 and ASPC-1 pancreatic cancer cells were treated with erianin at different concentrations. Cell viability and proliferation were assessed using the Cell Counting Kit-8 (CCK-8) assay and colony formation assay. Cell cycle distribution was analyzed by flow cytometry. Ferroptosis was evaluated by measuring levels of Fe²⁺, total iron, and lipid reactive oxygen species (ROS). Western blotting was used to detect</mark> the expression of cell cycle regulators and ferroptosis-related proteins. Results: Erianin significantly suppressed pancreatic cancer cell viability and proliferation in a dose-dependent manner. It induced G0/G1 phase arrest, accompanied by downregulation of cyclin D1 and cyclin A. Furthermore, erianin promoted ferroptosis, as evidenced by increased Fe²⁺, total iron, and lipid ROS levels, along with reduced glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) expression. The ferroptosis inhibitor Ferrostatin-1 reversed these effects, validating ferroptosis as a critical mechanism in erianin's anti-cancer activity. Conclusion: Erianin exerts potent anti-tumor effects on pancreatic cancer cells by inducing cell cycle arrest and ferroptosis. These findings establish erianin as a promising therapeutic candidate for pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.